LALPATHLAB - Swing Trade Analysis with AI Signals

Last Updated Time : 19 Sept 25, 2:15 pm

Swing Trade Rating: 4.0

📊 Technical & Momentum Overview

✅ Strengths

Price Action: Trading above both 50 DMA (₹3,185) and 200 DMA (₹2,964), confirming short- and medium-term strength.

MACD (18.4): Positive crossover, indicating bullish momentum.

RSI (52.8): Neutral-bullish zone, with room to rise before overbought.

Volume Surge: Current volume is ~46% higher than 1-week average—momentum supported.

ROCE (30.6%) & ROE (24.7%): Excellent capital efficiency.

EPS (₹62.0) vs P/E (53.2): Reasonable valuation for a premium diagnostics player.

Debt-to-Equity (0.02): Near-zero leverage—adds margin of safety.

DII Inflow (+1.83%): Strong domestic institutional support.

Qtr Profit Growth (+12.9%): Sequential earnings momentum.

⚠️ Watchouts

FII Outflow (–2.21%): Foreign investors reducing exposure.

PEG (4.07): Overvalued on growth-adjusted basis.

P/E (53.2) vs Industry PE (41.3): Slight valuation premium.

52W Index (73.4%): Mid-to-upper range—momentum breakout not yet confirmed.

PAT Qtr (₹129 Cr) vs Prev Qtr (₹148 Cr): Mild earnings contraction.

Brokerage projections suggest targets between ₹3,900 and ₹4,100 for FY25, supported by innovation and network expansion

1

.

🎯 Optimal Entry Price

Buy Zone: ₹3,180–₹3,220 (near 50 DMA and breakout base)

Momentum Entry: ₹3,300–₹3,320 if RSI crosses 55 and MACD remains strong

🚪 Exit Strategy (If Already Holding)

Target Exit: ₹3,600–₹3,650 (near 52W high and resistance zone)

Stop Loss: ₹3,080 (below 50 DMA and recent support)

Exit Trigger: RSI > 70 or MACD flattens

Selva, LALPATHLAB is shaping up as a technically sound swing candidate with strong fundamentals and domestic support. If you're building a diagnostics or healthcare basket, I can help you script MACD and RSI alerts or optimize entry logic across the sector.

1

tradewatch360.com

Edit in a page